NCT06022289 is a Phase 2 clinical trial of Pemigatinib in Solid Tumor, sponsored by Tianjin Medical University Second Hospital.

Who is sponsoring NCT06022289?

NCT06022289 is sponsored by Tianjin Medical University Second Hospital.

What drugs are being tested in NCT06022289?

Interventions in NCT06022289: Pemigatinib.

What condition does NCT06022289 study?

NCT06022289 studies Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification, FGF Receptor Gene Family Rearrangement, FGF Receptor Gene Translocation.

Is NCT06022289 still recruiting?

NCT06022289 is currently status unknown. Last updated 1 September 2023.

Last reviewed 2023-09-01 · How we verify

NCT06022289

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Status unknown Phase 2 Last updated 1 September 2023

What this trial tests

Phase 2 trial testing Pemigatinib in Solid Tumor in 20 participants. Status unknown.

Timeline

1 May 2023

Primary endpoint
1 May 2025

31 May 2025

Quick facts

Lead sponsor	Tianjin Medical University Second Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 May 2023
Primary completion	1 May 2025
Estimated completion	31 May 2025
Sites	1 location across China

Drugs / interventions tested

Pemigatinib (PEMIGATINIB) — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →
FGF Receptor Gene Mutation — all drugs for FGF Receptor Gene Mutation →
FGF Amplification — all drugs for FGF Amplification →
FGF Receptor Gene Family Rearrangement — all drugs for FGF Receptor Gene Family Rearrangement →

Sponsor

Tianjin Medical University Second Hospital

Who can join

18 and older, any sex, with Solid Tumor or FGF Receptor Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to demonstrate safety and efficacy of Pemigatinib in the treatment of advanced pan solid tumor patients with FGF/FGFR alterations.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.
Yang S, Fang Y, Ma Y, Wang F, et al · · 2025 · cited 22× · PMID 40268524 · DOI 10.1002/ctm2.70313
Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates.
Kim J, Kim HS, Nam M, Chae YK. · · 2025 · cited 3× · PMID 40576713 · DOI 10.1007/s10555-025-10274-2

Verify or expand the search:

Other trials of Pemigatinib

Trials testing the same drug.

NCT06906562 — A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metasta · Phase 2 · recruiting
NCT06653777 — Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells · Phase 2 · recruiting
NCT06439485 — Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarc · Phase 1, PHASE2 · recruiting
NCT06551896 — Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor · Phase 2 · not yet recruiting
NCT06389799 — A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) · Phase 2 · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Tianjin Medical University Second Hospital trials

Trials by the same sponsor.

NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07321197 — Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC): A Rand · NA · not yet recruiting
NCT07321210 — Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma · NA · recruiting
NCT07233252 — Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06022289 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Second Hospital
Last refreshed: 1 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06022289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing